- recruitingPHASE3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
This study looks at a daily tablet called upadacitinib for severe alopecia areata, a condition where your immune system attacks hair follicles, causing hair loss. It aims to see how safe and effective it is for teenagers and adults.
United States · Argentina · Australia - recruitingPHASE2
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
This study is testing a new medicine, LY4005130, for severe alopecia areata (hair loss). We want to see how well it helps hair grow back compared to a dummy treatment, and what side effects it might have.
United States · Canada · China - active not recruitingPHASE2, PHASE3
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
This study is looking into the long-term safety and effectiveness of a new medicine, CTP-543, for adults with moderate to severe hair loss caused by alopecia areata. It’s for people who have already tried CTP-543 in a previous study.
United States · Canada - recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
This study looks at how well a new medicine called Ritlecitinib works for people with a type of hair loss called alopecia areata in everyday life. It will check patient details, how the medicine is used, and how patients feel about their treatment.
United States · China · France - authorisedTherapeutic exploratory (Phase II)
J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata
This study is testing a new medicine, LY4005130, for adults with severe alopecia areata. It's a key step to see if the medicine can help hair grow back and if it's safe. Some people will get the medicine, others a dummy treatment, to compare results.
Netherlands - ongoing, recruitingTherapeutic confirmatory (Phase III)
B7981032 - A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA
This study is looking at a new medicine called Ritlecitinib to see if it's safe and helps adults and teenagers with alopecia areata. It's a long-term study to understand the side effects and how well it works over time.
Germany · Spain · Poland - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, randomized, double-blind, placebo-controlled, parallel group, 3-arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in adult participants with severe alopecia areata
This study is testing a new medicine, amlitelimab, for severe alopecia areata. It's looking at how well the medicine helps hair regrow and if it's safe. Some people will get the medicine, and others will get a dummy treatment, to see the real effects.
Italy · Netherlands · Czechia - recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study looks at how skin conditions like alopecia areata, vitiligo, and hidradenitis suppurativa affect daily life for teenagers and adults. Researchers want to understand the challenges these conditions bring to people all over the world.
Argentina · Canada · Colombia - active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
This study is looking into a new medicine called amlitelimab for people with severe alopecia areata. It wants to see if the medicine is safe and helps hair grow back. Some people will get the medicine, others a dummy treatment, to compare the results.
United States · Argentina · Australia - authorisedTherapeutic confirmatory (Phase III)
B7981028 - A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031
This study is looking long-term at a medicine called ritlecitinib for severe alopecia areata, a condition causing hair loss. It's checking how safe and effective the medicine is in people who were in earlier trials. The goal is to see if it helps with hair regrowth and overall well-being.
Italy · France · Czechia - active not recruitingPHASE3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
This study is looking at two different strengths (50mg and 100mg) of a medicine called ritlecitinib for people aged 12 and over with alopecia areata. It aims to understand how safe and effective the 100mg dose is for hair regrowth.
United States · Canada · China